You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluticasone furoate
Accession NumberDB08906
TypeSmall Molecule
GroupsApproved
DescriptionFluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Despite the similarity in the names, fluticasone furoate and fluticasone propionate are different drugs with different properties. It is marketed under the brand name, Veramyst in the US by GlaxoSmithKline for the management of chronic obstructive pulmonary disease (COPD). FDA approved on April 27, 2007. Fluticasone furoate is available as a combination product with vilanterol, a long-acting beta-2 agonist, under the tradename Breo Ellipta. Approved by the FDA in 2013, its use is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
Structure
Thumb
Synonyms
Fluticasonum furoas
Furoate de fluticasone
Furoato de fluticasona
External Identifiers
  • GSK 685698
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arnuity Elliptapowder100 mcginhalation; oralGlaxosmithkline Inc2016-01-26Not applicableCanada
Arnuity Elliptapowder200 mcginhalation; oralGlaxosmithkline Inc2015-12-14Not applicableCanada
Arnuity Elliptapowder100 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2014-08-20Not applicableUs
Arnuity Elliptapowder200 ug/1respiratory (inhalation)Glaxo Smith Kline Llc2014-08-20Not applicableUs
AvamysNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Limited2008-01-11Not applicableEu
AvamysNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Limited2008-01-11Not applicableEu
Avamysspray, metered dose27.5 mcgnasalGlaxosmithkline Inc2007-10-22Not applicableCanada
AvamysNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Limited2008-01-11Not applicableEu
Veramystspray, metered27.5 ug/1nasalGlaxo Smith Kline Llc2007-05-15Not applicableUs
Veramystspray, metered27.5 ug/1nasalREMEDYREPACK INC.2013-06-07Not applicableUs
Veramystspray, metered27.5 ug/1nasalPhysicians Total Care, Inc.2010-09-07Not applicableUs
Veramystspray, metered27.5 ug/1nasalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-05-15Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlisadeNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Ltd.2008-10-06Not applicableEu
AlisadeNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Ltd.2008-10-06Not applicableEu
AlisadeNasal spray suspension27.5 micrograms/sprayIntranasal useGlaxo Group Ltd.2008-10-06Not applicableEu
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Breo ElliptaGlaxo Smith Kline Llc
SaltsNot Available
Categories
UNIIJS86977WNV
CAS number397864-44-7
WeightAverage: 538.576
Monoisotopic: 538.163693965
Chemical FormulaC27H29F3O6S
InChI KeyInChIKey=XTULMSXFIHGYFS-VLSRWLAYSA-N
InChI
InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl furan-2-carboxylate
SMILES
[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androgen-skeleton
  • Androstane-skeleton
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Furoate
  • Heteroaromatic compound
  • Furan
  • Cyclic alcohol
  • Cyclic ketone
  • Thiocarboxylic acid ester
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Sulfenyl compound
  • Thioether
  • Thiocarboxylic acid or derivatives
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.
PharmacodynamicsFluticasone furoate binds to human glucocorticoid receptor more potently than dexamethasone (29.9-times) and fluticasone propionate (1.7-times). It also is highly retained in respiratory tissue. The significance of this finding is that fluticasone furoate may have a more pronounced and prolonged anti-inflammatory effect, which allows for once-daily dosing. It does not have any effect on the QTc interval. Furthermore, fluticasone furoate was not found to affect the hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma.
Mechanism of actionFluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma.
Related Articles
AbsorptionFollowing intranasal administration of fluticasone furoate, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive first-pass metabolism in the liver and gut, resulting in negligible systemic exposure. Even at the highest recommended intranasal dose of 110 mcg once daily, plasma concentrations were not quantifiable. This is an especially useful feature as it lowers the incidence of adverse events associated with corticosteroid use. If administered using oral solution and intravenous dosing, 30% of the drug is absorbed and rapidly cleared from the plasma. Absolute bioavailability, intranasal route = 0.5%; Absolute bioavailability, oral route = 1.26%; Mean lung absorption time = 7 hours (regardless of formulation);
Volume of distribution

Steady state, IV administration = 608 L

Protein binding>99% protein bound.
Metabolism

Fluticasone furoate does not undergo cleavage into its two separate components, fluticasone and the furoate moiety. It undergoes extensive hepatic metabolism via CYP3A4. The principal route of metabolism is hydrolysis of the S-fluoromethyl carbothioate function to form the inactive 17β-carboxylic acid metabolite. Studies suggest that enterocytes may be involved in the metabolism of unabsorbed drug.

Route of eliminationFluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered dose, respectively. Fluticasone furoate is extensively metabolized so very little is excreted unchanged.
Half lifeElimination phase half-life, IV dose = 15.1 hours; Elimination phase half-life, inhaled = 17 - 24 hours;
Clearance

Total plasma clearance = 58.7 L/h

ToxicityThe most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9666
Caco-2 permeable-0.5222
P-glycoprotein substrateSubstrate0.7675
P-glycoprotein inhibitor IInhibitor0.784
P-glycoprotein inhibitor IIInhibitor0.604
Renal organic cation transporterNon-inhibitor0.8329
CYP450 2C9 substrateNon-substrate0.8023
CYP450 2D6 substrateNon-substrate0.8893
CYP450 3A4 substrateSubstrate0.7205
CYP450 1A2 substrateNon-inhibitor0.6493
CYP450 2C9 inhibitorNon-inhibitor0.7288
CYP450 2D6 inhibitorNon-inhibitor0.8305
CYP450 2C19 inhibitorNon-inhibitor0.6388
CYP450 3A4 inhibitorInhibitor0.9211
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.69
Ames testNon AMES toxic0.747
CarcinogenicityNon-carcinogens0.9079
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6232 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.566
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Nasal spray suspensionIntranasal use27.5 micrograms/spray
Powderinhalation; oral100 mcg
Powderinhalation; oral200 mcg
Powderrespiratory (inhalation)100 ug/1
Powderrespiratory (inhalation)200 ug/1
Spray, metered dosenasal27.5 mcg
Powderinhalation
Powderrespiratory (inhalation)
Spray, meterednasal27.5 ug/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5873360 No1996-02-232016-02-23Us
US6537983 No2001-08-032021-08-03Us
US6759398 No2001-08-032021-08-03Us
US6858596 No2001-08-032021-08-03Us
US6878698 No2001-08-032021-08-03Us
US7101866 No2001-08-032021-08-03Us
US7439393 No2002-09-112022-09-11Us
US7541350 No2001-08-032021-08-03Us
US7629335 No2001-08-032021-08-03Us
US7776895 No2002-09-112022-09-11Us
US8062264 No2006-04-052026-04-05Us
US8113199 No2007-10-232027-10-23Us
US8147461 No2008-10-152028-10-15Us
US8161968 No2008-02-052028-02-05Us
US8201556 No2009-02-052029-02-05Us
US8347879 No2008-07-152028-07-15Us
US8511304 No2007-06-142027-06-14Us
US8534281 No2009-08-102029-08-10Us
US8746242 No2010-10-112030-10-11Us
US8752543 No2006-04-052026-04-05Us
USRE44874 No2003-03-232023-03-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
pKa6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0434 mg/mLALOGPS
logP3.73ALOGPS
logP4.13ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity130.08 m3·mol-1ChemAxon
Polarizability51.55 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Adrienne KOVACSNE-MEZEI, Roman Gabriel, Alexandr Jegorov, “POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF.” U.S. Patent US20100240629, issued September 23, 2010.

US20100240629
General References
  1. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. [PubMed:23578031 ]
  2. Tamm M, Richards DH, Beghe B, Fabbri L: Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106 Suppl 1:S9-19. doi: 10.1016/S0954-6111(12)70005-7. [PubMed:23273165 ]
  3. Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x. [PubMed:23184737 ]
External Links
ATC CodesR03AK10R01AD12R03BA09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (469 KB)
MSDSDownload (70.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.
AcetaminophenThe serum concentration of Fluticasone furoate can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone furoate.
AfatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Albendazole.
AldesleukinFluticasone furoate may decrease the antineoplastic activities of Aldesleukin.
AldosteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Fluticasone furoate can be increased when it is combined with Alfentanil.
Aluminum hydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum phosphate.
AmantadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amantadine.
AmbenoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ambenonium.
Aminohippuric acidThe serum concentration of Fluticasone furoate can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone furoate.
AmiodaroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amlodipine.
Amphotericin BFluticasone furoate may increase the hypokalemic activities of Amphotericin B.
AmprenavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Aprepitant.
AstemizoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Fluticasone furoate can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Fluticasone furoate can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Atorvastatin.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone furoate.
AzelastineThe serum concentration of Fluticasone furoate can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Azithromycin.
BazedoxifeneThe serum concentration of Fluticasone furoate can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFluticasone furoate may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe serum concentration of Fluticasone furoate can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluticasone furoate.
BepridilThe serum concentration of Fluticasone furoate can be increased when it is combined with Bepridil.
BexaroteneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Fluticasone furoate can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe bioavailability of Fluticasone furoate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Fluticasone furoate can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Fluticasone furoate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Fluticasone furoate can be increased when it is combined with Bromocriptine.
BumetanideFluticasone furoate may increase the hypokalemic activities of Bumetanide.
BuprenorphineThe serum concentration of Fluticasone furoate can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Fluticasone furoate can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Fluticasone furoate can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Fluticasone furoate can be increased when it is combined with Caffeine.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone furoate.
Calcium carbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Calcium carbonate.
CanagliflozinThe serum concentration of Fluticasone furoate can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Fluticasone furoate can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Fluticasone furoate can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Ceritinib.
CeritinibFluticasone furoate may increase the hyperglycemic activities of Ceritinib.
ChloroquineThe serum concentration of Fluticasone furoate can be increased when it is combined with Chloroquine.
ChlorothiazideFluticasone furoate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorprothixene.
ChlorthalidoneFluticasone furoate may increase the hypokalemic activities of Chlorthalidone.
CholesterolThe serum concentration of Fluticasone furoate can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Fluticasone furoate can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Fluticasone furoate can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Fluticasone furoate can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Fluticasone furoate can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Fluticasone furoate can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Fluticasone furoate can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Fluticasone furoate can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Fluticasone furoate can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Fluticasone furoate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone furoate.
CoumaphosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Coumaphos.
CrizotinibThe metabolism of Fluticasone furoate can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Fluticasone furoate can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Dactinomycin.
DarunavirThe serum concentration of Fluticasone furoate can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Daunorubicin.
DecamethoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Decamethonium.
DeferasiroxThe serum concentration of Fluticasone furoate can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Deferasirox.
DelavirdineThe metabolism of Fluticasone furoate can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Demecarium.
DesipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Fluticasone furoate can be increased when it is combined with Dextromethorphan.
DichlorvosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Dichlorvos.
DiclofenacThe serum concentration of Fluticasone furoate can be increased when it is combined with Diclofenac.
DienestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone furoate.
DigoxinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Fluticasone furoate can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneFluticasone furoate may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Fluticasone furoate can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Dipyridamole.
DonepezilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Donepezil.
DoxazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Fluticasone furoate can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Fluticasone furoate can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Fluticasone furoate can be decreased when combined with Dronedarone.
EchothiophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Edrophonium.
EfavirenzThe serum concentration of Fluticasone furoate can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Fluticasone furoate can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Fluticasone furoate can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estradiol.
EstramustineThe serum concentration of Fluticasone furoate can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.
Etacrynic acidFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol.
EtoposideThe serum concentration of Fluticasone furoate can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Fluticasone furoate can be increased when it is combined with Fentanyl.
FenthionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fenthion.
FexofenadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fluticasone furoate can be increased when it is combined with Fidaxomicin.
FluconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluoxetine.
FluoxymesteroneFluticasone furoate may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe serum concentration of Fluticasone furoate can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Fluticasone furoate can be increased when it is combined with Flurazepam.
FluvoxamineThe metabolism of Fluticasone furoate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fluticasone furoate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Fosphenytoin.
FurosemideFluticasone furoate may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gallamine Triethiodide.
GefitinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Fluticasone furoate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ginkgo biloba.
GlyburideThe serum concentration of Fluticasone furoate can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Fluticasone furoate can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluticasone furoate.
Gramicidin DThe serum concentration of Fluticasone furoate can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Fluticasone furoate can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Fluticasone furoate can be increased when it is combined with Haloperidol.
HexestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone furoate.
HydrochlorothiazideFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Hydrocortisone.
HydroflumethiazideFluticasone furoate may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Fluticasone furoate can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Fluticasone furoate can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the hypokalemic activities of Fluticasone furoate.
IndapamideFluticasone furoate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Fluticasone furoate can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Fluticasone furoate can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone furoate.
IsradipineThe metabolism of Fluticasone furoate can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Lapatinib.
LevofloxacinThe serum concentration of Fluticasone furoate can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Fluticasone furoate can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Fluticasone furoate can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Fluticasone furoate can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Fluticasone furoate can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Fluticasone furoate can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.
LovastatinThe metabolism of Fluticasone furoate can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Fluticasone furoate can be decreased when it is combined with Lumacaftor.
MagaldrateThe bioavailability of Fluticasone furoate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Malathion.
MaprotilineThe serum concentration of Fluticasone furoate can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Fluticasone furoate can be increased when it is combined with Mefloquine.
MefloquineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Mefloquine.
Megestrol acetateThe serum concentration of Fluticasone furoate can be increased when it is combined with Megestrol acetate.
MemantineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Memantine.
MeprobamateThe serum concentration of Fluticasone furoate can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone furoate.
MestranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Mestranol.
MethadoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Methadone.
MethyclothiazideFluticasone furoate may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFluticasone furoate may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFluticasone furoate may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Fluticasone furoate can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Fluticasone furoate can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.
MifepristoneThe therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Minaprine.
MitomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitoxantrone.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluticasone furoate.
ModafinilThe serum concentration of Fluticasone furoate can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Fluticasone furoate can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Fluticasone furoate can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Fluticasone furoate can be increased when it is combined with Neostigmine.
NeostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Neostigmine.
NetupitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Fluticasone furoate can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nicardipine.
NicorandilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nicorandil.
NifedipineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Fluticasone furoate can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Osimertinib.
OxandroloneFluticasone furoate may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFluticasone furoate may increase the fluid retaining activities of Oxymetholone.
P-NitrophenolThe serum concentration of Fluticasone furoate can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Fluticasone furoate can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Fluticasone furoate can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Fluticasone furoate can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Fluticasone furoate can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluticasone furoate.
PhenytoinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Physostigmine.
PimozideThe serum concentration of Fluticasone furoate can be increased when it is combined with Pimozide.
PiretanideFluticasone furoate may increase the hypokalemic activities of Piretanide.
Platelet Activating FactorThe serum concentration of Fluticasone furoate can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphateThe serum concentration of Fluticasone furoate can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFluticasone furoate may increase the hypokalemic activities of Polythiazide.
PonatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Fluticasone furoate can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Fluticasone furoate can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Fluticasone furoate can be increased when it is combined with Protriptyline.
PyridostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pyridostigmine.
QuercetinThe serum concentration of Fluticasone furoate can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinacrine.
QuinestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinestrol.
QuinethazoneFluticasone furoate may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rabies vaccine.
RanitidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluticasone furoate.
ReboxetineThe serum concentration of Fluticasone furoate can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Fluticasone furoate can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Reserpine.
RifabutinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Fluticasone furoate can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rivastigmine.
RolapitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Rolapitant.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone furoate.
SaquinavirThe serum concentration of Fluticasone furoate can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Fluticasone furoate can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Fluticasone furoate can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Fluticasone furoate can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Fluticasone furoate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Fluticasone furoate can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Fluticasone furoate can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Fluticasone furoate can be decreased when it is combined with Sirolimus.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluticasone furoate.
SorafenibThe serum concentration of Fluticasone furoate can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Fluticasone furoate can be decreased when it is combined with St. John's Wort.
StanozololFluticasone furoate may increase the fluid retaining activities of Stanozolol.
StaurosporineThe serum concentration of Fluticasone furoate can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Fluticasone furoate can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Fluticasone furoate can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Fluticasone furoate can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Sunitinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe serum concentration of Fluticasone furoate can be increased when it is combined with Tacrine.
TacrineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tacrine.
TacrolimusThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluticasone furoate.
TelaprevirThe serum concentration of Fluticasone furoate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Fluticasone furoate can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Fluticasone furoate can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Fluticasone furoate can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Fluticasone furoate can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tesmilifene.
TestosteroneFluticasone furoate may increase the fluid retaining activities of Testosterone.
TestosteroneThe serum concentration of Fluticasone furoate can be increased when it is combined with Testosterone.
TiboloneThe serum concentration of Fluticasone furoate can be increased when it is combined with Tibolone.
TicagrelorThe serum concentration of Fluticasone furoate can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Fluticasone furoate can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Tolvaptan.
TorasemideFluticasone furoate may increase the hypokalemic activities of Torasemide.
TrazodoneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trazodone.
TrichlorfonThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Trichlorfon.
TrichlormethiazideFluticasone furoate may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Fluticasone furoate can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Fluticasone furoate can be increased when it is combined with Troleandomycin.
TubocurarineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tubocurarine.
VenlafaxineThe metabolism of Fluticasone furoate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Fluticasone furoate can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Voriconazole.
WarfarinFluticasone furoate may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Zeranol.
ZimelidineThe serum concentration of Fluticasone furoate can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM: Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008 Nov;36(11):2337-44. doi: 10.1124/dmd.108.022137. Epub 2008 Aug 11. [PubMed:18694910 ]
Comments
comments powered by Disqus
Drug created on June 16, 2013 17:03 / Updated on September 30, 2016 02:27